NovoCure Limited (NVCR) stock surged 17 percent on Thursday after it announced that FDA has approved its Premarket Approval or PMA application based on the LUNAR, which mentioned the usage of TTFields therapy for the treatment of non-small cell lung cancer or NSCLC.
Currently, the oncology company's stock is climbing 17.79 percent to $14.60 over the previous close of $12.42 on a volume of 1,128,937. It had traded from $10.87 to $95.91 in the past 52-week period.
The company expects to receive a regulatory decision from FDA about LUNAR in the second half of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.